# GLP-1s and Cancer: The Randomized Answer

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-19 | Updated: 2026-10-30

Canonical page: https://glpwatchdog.org/research/glp1-cancer-risk-the-randomized-answer

> Randomized evidence finds little or no effect on obesity-related cancers: pancreatic somewhere between 9 fewer and 6 more per 10,000. The trials were not designed to look for cancer and had short follow-up.

## Key points

- Pancreatic OR 0.84, breast 0.95, kidney 1.12, with all intervals spanning no effect.
- In absolute terms: 9 fewer to 6 more pancreatic cancers per 10,000 people.
- 'The included trials were not designed to evaluate cancer outcomes and had short follow-up.'
- Consistent across low-risk-of-bias trials and across drugs, which is what makes a null believable.

We have already looked at what [the observational cohorts say about cancer](https://glpwatchdog.org/research/glp1-and-cancer-risk-what-the-cohorts-show), and at how badly one of them behaved. Here is the randomized answer, from a systematic review in the Annals of Internal Medicine: GLP-1 drugs **may have little or no effect** on obesity-related cancers.[1] That is less reassuring than it sounds, for a reason the review itself gives.

## What the trials showed

*Pooled randomized evidence, at moderate certainty. Absolute ranges are per 10,000 people.*

| Cancer | Odds ratio | Absolute range |
| --- | --- | --- |
| Pancreatic | 0.84 (95% CI 0.53–1.35) | 9 fewer to 6 more |
| Breast | 0.95 (95% CI 0.60–1.49) | 10 fewer to 12 more |
| Kidney | 1.12 (95% CI 0.78–1.60) | 5 fewer to 13 more |

For colorectal, esophageal, liver, gallbladder, ovarian and endometrial cancer, and for multiple myeloma and meningioma, the review found, at low certainty, that the drugs may have little or no effect. For gastric cancer, the effect is very uncertain.[1]

> **Read the right-hand column rather than the odds ratios.** “Nine fewer to six more pancreatic cancers per ten thousand people” tells you what is at stake: an effect small enough in either direction that it would be invisible to any individual. An odds ratio of 0.84 sounds like a 16% reduction, but its interval runs from 0.53 to 1.35, so the data are also compatible with an increase.

## Why 'no effect' is not the same as 'safe'

The review states its central limitation directly: the included trials were not designed to evaluate cancer outcomes and had short follow-up.[1] That single sentence governs everything above, and it applies as much to [an observational study in adults without diabetes](https://glpwatchdog.org/research/cancer-risk-in-people-without-diabetes) whose median follow-up was two years.

> Cancer takes years to appear, and these trials ran for one or two.

Cancer outcomes in these studies were recorded as adverse events, not hunted for as endpoints, in trials built around weight or cardiovascular disease. The same structural weakness produced the inflated dementia signal we covered in [the EVOKE article](https://glpwatchdog.org/research/semaglutide-alzheimers-evoke-result), only here it cuts toward a null rather than a false positive.

## What is reassuring, and what is not

- **Reassuring:** results held consistent in sensitivity analyses restricted to low-risk-of-bias trials, and across semaglutide and tirzepatide specifically, and across subgroups by follow-up, population, dose and duration of action.[1] Consistency is the property that makes a null believable.
- **Reassuring:** nothing points toward increased risk. The intervals sit around no effect rather than leaning toward harm.
- **Not reassuring:** the follow-up is far too short for the question. Longer-term studies are needed, as the review says.
- **Not reassuring:** the confidence intervals are wide enough to accommodate meaningful effects in either direction for several cancers.

## How this sits with the cohort evidence

The cohorts suggested a small protective association: a hazard ratio of 0.87 for obesity-related cancers across 919,609 people.[2] The randomized trials suggest little or no effect. Those are not in conflict.

The cohorts have the years the trials lack and the confounding the trials do not. The trials have the randomization the cohorts do not and none of the time. Each is strong where the other is weak. Taken together they point to probably nothing dramatic in either direction, and nobody yet has the decade of data that would settle it.

The thyroid C-cell warning that appears on every label in this class is a separate question with its own evidence, covered in [the thyroid cancer article](https://glpwatchdog.org/research/glp1-thyroid-cancer-risk). What the breast cancer row means alongside breast size, pain and mammograms is in [GLP-1 drugs and breast changes](https://glpwatchdog.org/research/glp1-and-breast-changes).

## Frequently asked questions

### Do GLP-1 drugs cause cancer?

Randomized evidence does not suggest so. A systematic review found the drugs may have little or no effect on obesity-related cancers, with confidence intervals for pancreatic, breast and kidney cancer sitting around no effect at moderate certainty.

### Do they prevent cancer?

The randomized evidence does not support that either. Observational cohorts have suggested a small protective association, but the trials show little or no effect. Both can be true if the real effect is small.

### Why is 'no effect' not fully reassuring?

Because the review says the included trials were not designed to evaluate cancer outcomes and had short follow-up. Cancer takes years to develop, and these trials ran one to two. An absence of signal in that window says more about the window than about the drug.

### What about pancreatic cancer specifically?

The pooled odds ratio was 0.84 with a confidence interval from 0.53 to 1.35, corresponding to somewhere between 9 fewer and 6 more cases per 10,000 people. That is a range spanning both directions and small enough to be invisible to any individual.

### What would settle this?

Longer-term studies, which the review explicitly calls for. Any firm claim in either direction today is running ahead of a follow-up period that does not yet exist.

## References

1. Ko A, Chang YC, Bahar F, et al. Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists: A Systematic Review and Meta-Analysis. Annals of Internal Medicine. 2026. PMID: 41359966. https://pubmed.ncbi.nlm.nih.gov/41359966/
2. Mao X, Zhang X, Henry L, et al. Association between glucagon-like peptidase 1 receptor agonist and obesity-related cancer in overweight or obese patients with type 2 diabetes: a nationwide cohort study. Journal of the National Cancer Institute. 2025. PMID: 40632592. https://pubmed.ncbi.nlm.nih.gov/40632592/

---

Cite as: GLP Watchdog, Nora Bissett, "GLP-1s and Cancer: The Randomized Answer", published 2026-08-19, updated 2026-10-30. https://glpwatchdog.org/research/glp1-cancer-risk-the-randomized-answer

Canonical HTML page: https://glpwatchdog.org/research/glp1-cancer-risk-the-randomized-answer

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
